BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 8190111)

  • 1. Activation of rat Kupffer cells to tumoricidal cells by the immunomodulator muramyl tripeptide-phosphatidylethanolamine incorporated into the novel drug carrier lactosylated low density lipoprotein.
    van de Water B; van Berkel TJ; Kuiper J
    Mol Pharmacol; 1994 May; 45(5):971-7. PubMed ID: 8190111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional muramyl tripeptide phosphatidylethanolamine administration enhances hepatic immune function and tumor surveillance.
    Karpoff HM; Jarnagin W; Delman K; Fong Y
    Surgery; 2000 Aug; 128(2):213-8. PubMed ID: 10922994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of macrophage antitumor activity by acetylated low density lipoprotein containing lipophilic muramyl tripeptide.
    Shaw JM; Futch WS; Schook LB
    Proc Natl Acad Sci U S A; 1988 Aug; 85(16):6112-6. PubMed ID: 3413079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide.
    Fidler IJ; Fogler WE; Brownbill AF; Schumann G
    J Immunol; 1987 Jun; 138(12):4509-14. PubMed ID: 3584979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes.
    Fogler WE; Fidler IJ
    Int J Immunopharmacol; 1987; 9(2):141-50. PubMed ID: 3583507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.
    Maeda M; Knowles RD; Kleinerman ES
    Cancer Commun; 1991; 3(10-11):313-21. PubMed ID: 1722107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Kleinerman ES
    Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
    Asano T; McWatters A; An T; Matsushima K; Kleinerman ES
    J Pharmacol Exp Ther; 1994 Feb; 268(2):1032-9. PubMed ID: 8113959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of murine Kupffer cell tumoricidal activity by liposomes containing lipophilic muramyl dipeptide.
    Phillips NC; Rioux J; Tsao MS
    Hepatology; 1988; 8(5):1046-50. PubMed ID: 2971013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.
    Nardin A; Lefebvre ML; Labroquère K; Faure O; Abastado JP
    Curr Cancer Drug Targets; 2006 Mar; 6(2):123-33. PubMed ID: 16529542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional characteristics of the rat liver macrophage population after a single intravenous injection of liposome-encapsulated muramyl peptides.
    Hoedemakers RM; Vossebeld PJ; Daemen T; Scherphof GL
    J Immunother Emphasis Tumor Immunol; 1993 May; 13(4):252-60. PubMed ID: 8334109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lactosylated low density lipoprotein: a potential carrier for the site-specific delivery of drugs to Kupffer cells.
    Bijsterbosch MK; Ziere GJ; Van Berkel TJ
    Mol Pharmacol; 1989 Sep; 36(3):484-9. PubMed ID: 2550781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of nitric oxide production and tumoricidal properties in murine macrophages by a new synthetic lipopeptide JBT3002 encapsulated in liposomes.
    Eue I; Kumar R; Dong Z; Killion JJ; Fidler IJ
    J Immunother; 1998 Sep; 21(5):340-51. PubMed ID: 9789196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostaglandin E2 affects differently the release of inflammatory mediators from resident macrophages by LPS and muramyl tripeptides.
    Dieter P; Hempel U; Kamionka S; Kolada A; Malessa B; Fitzke E; Tran-Thi TA
    Mediators Inflamm; 1999; 8(6):295-303. PubMed ID: 10815618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice.
    Fogler WE; Wade R; Brundish DE; Fidler IJ
    J Immunol; 1985 Aug; 135(2):1372-7. PubMed ID: 4008926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The lipophilic muramyltripeptide MTP-PE, a biological response modifier, is an activator of protein kinase C.
    Meyer T; Fabbro D; Eppenberger U; Matter A
    Biochem Biophys Res Commun; 1986 Nov; 140(3):1043-50. PubMed ID: 3465326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes.
    Sone S; Mutsuura S; Ogawara M; Tsubura E
    J Immunol; 1984 Apr; 132(4):2105-10. PubMed ID: 6699409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In situ activation of mouse alveolar macrophages by aerosolized liposomal IFN-gamma and muramyl tripeptide.
    Goldbach P; Dumont S; Kessler R; Poindron P; Stamm A
    Am J Physiol; 1996 Mar; 270(3 Pt 1):L429-34. PubMed ID: 8638735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells.
    Kurzman ID; Shi F; Vail DM; MacEwen EG
    Cancer Biother Radiopharm; 1999 Apr; 14(2):121-8. PubMed ID: 10850295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MTP-PE: induction of tumoricidal leukocytes in the lungs of rats.
    Brownbill AF; Schumann G
    Cancer Detect Prev; 1988; 12(1-6):161-8. PubMed ID: 3180123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.